Align Technology Announces Leadership Transition with Kevin Conroy as New Chairman Starting 2026

Align Technology (ALGN) announces a pivotal leadership transition as C. Raymond Larkin, Jr. retires from his position as Chairman, effective July 1, 2026. Kevin Conroy, an independent director with substantial experience in the healthcare sector, is set to take over this critical role. Conroy previously led Exact Sciences, a biotech firm renowned for achieving impressive annual revenues of $3.25 billion. His extensive experience also includes a seat on the board of Abbott Laboratories, where he gained comprehensive governance and commercialization expertise. This transition is more than just a change in leadership; it signifies Align's commitment to strengthening its governance and exploring new growth avenues in the health-tech industry.

Leadership Transition to Elevate Governance Structure

The transition aims to bolster Align Technology's governance structure while reaffirming its strategic focus on core health-tech initiatives. Larkin, who has served as Chairman for many years, will remain on Align's Board until December 31, 2026, to facilitate a smooth handover and provide ongoing support. His guidance during this transitional period is expected to be invaluable as Conroy steps into the role, allowing for continuity while ushering in fresh ideas and insights.

A New Era for Align Technology

Align Technology is poised for a new chapter under Conroy's leadership, with expectations that his background will enhance the company's strategic direction. His prior experience leading a successful biotech company is anticipated to bring a new perspective to Align's operational practices and long-term strategies. As the health-tech sector rapidly evolves, Align's governance changes reflect a proactive approach to navigating the challenges and opportunities that lie ahead, ultimately aiming to strengthen its competitive position in a growing market.